View Older Stories View More Recent Stories

May 17, 2017 05:03PM Incyte (INCY) Reports New Data for Presentation at ASCO For Epacadostat in Combination with Keytruda
May 17, 2017 05:03PM First Data from Combination of Epacadostat with Opdivo® (nivolumab) Will Be Highlighted at ASCO 2017
May 17, 2017 05:02PM New Data for Presentation at ASCO 2017 Reinforce Clinical Profile of Epacadostat in Combination with Keytruda® (pembrolizumab)
May 4, 2017 07:00AM Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs
Apr 25, 2017 08:00AM Incyte to Present at Upcoming Investor Conferences
Apr 20, 2017 01:16PM Incyte (INCY) Says 15 ASCO Abstracts Will Highlights its Research
Apr 20, 2017 01:13PM Incyte's Immuno-oncology and Targeted Therapy Clinical Portfolio to be Featured in More than 15 Abstracts at the 2017 ASCO Annual Meeting
Apr 18, 2017 08:00AM Incyte to Report First Quarter Financial Results
Apr 17, 2017 05:35AM Eli Lilly & Co. (LLY) & Incyte Corp. (INCY) Receive CRL from FDA for NDA of Baricitinib
Apr 14, 2017 10:05AM Eli Lilly (LLY), Incyte (INCY) Announce FDA CRL for RA Treatment Baricitinib
Apr 14, 2017 09:00AM U.S. FDA Issues Complete Response Letter for Baricitinib
Apr 14, 2017 09:00AM U.S. FDA Issues Complete Response Letter for Baricitinib
Apr 3, 2017 05:55AM Bristol-Myers Squibb (BMY) and Incyte (INCY) Advance Epacadostat and Opdivo Combo
Apr 2, 2017 06:59AM Bristol-Myers Squibb and Incyte to Advance the Combination of Opdivo (nivolumab) and Epacadostat into First-line Registrational Trials
Mar 31, 2017 07:02AM Incyte (INCY), Merck (MRK) Provide Details on Pact to Investigate Epacadostat and KEYTRUDA
Mar 31, 2017 07:00AM Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA® (pembrolizumab)
Mar 2, 2017 07:30AM Incyte’s Targeted Therapy and Immuno-oncology Portfolio to be Featured in 20 Abstracts at the AACR Annual Meeting 2017
Feb 28, 2017 09:00AM Incyte Raises Awareness for Myeloproliferative Neoplasms as Part of Rare Disease Day 2017
Feb 23, 2017 07:58AM Incyte Announces Oncology Research Alliance with the Abramson Cancer Center at the University of Pennsylvania
Feb 21, 2017 08:00AM Incyte to Present at Upcoming Investor Conferences
Feb 16, 2017 07:35AM Lilly (LLY) and Incyte (INCY) Announces Additional Results from Pivotal RA-BEAM Study Published in NEJM
Feb 15, 2017 05:56PM Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adal
Feb 14, 2017 03:41PM JANA Partners Enters Aetna (AET), Bristol-Myers Squibb (BMY), Lamb Weston (LW), Salesforce (CRM) (more...) - 13F
Feb 14, 2017 07:07AM Incyte (INCY), Agenus (AGEN) Announce Amendment to Collaboration Agreement
Feb 14, 2017 07:00AM Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs
Feb 14, 2017 07:00AM Incyte and Agenus Amend Collaboration Agreement
Feb 13, 2017 04:30PM Lilly (LLY), Incyte (INCY) Announce EC Approval for Once-Daily Olumiant Tablets to Treat Moderate-to-Severe Active RA
Feb 13, 2017 04:21PM European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis
Jan 30, 2017 06:49AM Incyte (INCY) and Calithera Biosciences (CALA) Enter Pact to Develop and Commercialize CB-1158
Jan 30, 2017 06:48AM Incyte (INCY), Calithera Biosciences (CALA) Enter Collaboration to Develop and Commercialize CB-1158
Jan 30, 2017 06:45AM Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor
Jan 30, 2017 06:45AM Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor
Jan 24, 2017 08:00AM Incyte to Report Fourth Quarter and Year-End Financial Results
Jan 17, 2017 07:20AM Eli Lilly & Co. (LLY), Incyte (INCY) Announce FDA Extends Review Period for Baricitinib
Jan 13, 2017 04:51PM U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment
Jan 9, 2017 08:05AM Incyte (INCY), Merck (MRK) to Advance Clinical Development of Epacadostat with KEYTRUDA Combo
Jan 9, 2017 08:00AM Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA® (pembrolizumab)
Dec 30, 2016 04:15PM Incyte Announces First Patient Treated in Pivotal Clinical Trial Program for Ruxolitinib (Jakafi®) in Graft-versus-Host Disease
Dec 21, 2016 07:02AM Merus N.V. (MRUS) and Incyte (INCY) Announce Research Collaboration
Dec 21, 2016 07:00AM Incyte and Merus Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies
Dec 16, 2016 07:50AM Eli Lilly & Co. (LLY), Incyte (INCY) Announce CHMP Recommendation of Baricitinib for Adults with RA
Dec 16, 2016 07:48AM CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA)
Dec 13, 2016 08:00AM Incyte to Present at Upcoming Investor Conference
Dec 5, 2016 06:14AM Incyte (INCY) Presents Pooled Analysis from COMFORT-I, COMFORT-II Trials; OS Findings Supported
Dec 4, 2016 01:08PM Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi® (ruxolitinib)
Nov 14, 2016 09:29AM Eli Lilly & Co. (LLY), Incyte (INCY) Announce Significant Data from Two Baricitinib Phase 3s in RA
Nov 14, 2016 09:00AM New Analyses of Phase 3 Trials Show Improvements in Rheumatoid Arthritis Symptoms Following Treatment with Baricitinib Across Diverse Population of Patients
Nov 14, 2016 09:00AM Baricitinib Demonstrates Early Response Compared to Placebo and Significant Improvement Compared to Adalimumab in Patient-Reported Outcomes
Nov 14, 2016 07:49AM JANA Partners Enters Kate Spade (KATE), Select Medical (SEM), Twitter (TWTR) (more...)
Nov 3, 2016 10:32AM More Than 20 Abstracts Highlighting Data from Incyte’s Portfolio Accepted for Presentation at the 58th Annual ASH Meeting
View More Recent Stories View Older Stories